Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Cardiol Therapeutics in a report released on Monday, June 2nd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.97 EPS.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01.
Cardiol Therapeutics Price Performance
NASDAQ CRDL traded down $0.07 on Wednesday, reaching $1.38. 500,278 shares of the company's stock traded hands, compared to its average volume of 357,762. The stock has a market cap of $114.00 million, a PE ratio of -3.54 and a beta of 1.03. Cardiol Therapeutics has a 12 month low of $0.77 and a 12 month high of $3.12. The stock has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $1.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49.
Hedge Funds Weigh In On Cardiol Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in CRDL. Virtu Financial LLC purchased a new stake in Cardiol Therapeutics during the fourth quarter valued at about $61,000. Cetera Investment Advisers bought a new stake in shares of Cardiol Therapeutics in the 4th quarter valued at about $56,000. Envestnet Asset Management Inc. bought a new stake in shares of Cardiol Therapeutics in the 4th quarter valued at about $398,000. Atria Investments Inc purchased a new stake in Cardiol Therapeutics during the 4th quarter valued at about $174,000. Finally, PVG Asset Management Corp bought a new position in Cardiol Therapeutics during the 4th quarter worth approximately $624,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
